Preservative-free tafluprost/timolol fixed combination

a new opportunity in the treatment of glaucoma

Anastasios G P Konstas, G. Holló

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Medical therapy of glaucoma aims to maintain the patient’s visual function and quality of life. This generally commences with monotherapy, but it is often difficult to reach the predetermined target pressure with this approach. Fixed combinations (FCs) are therefore selected as the next step of the medical therapy algorithm. By employing a prostaglandin/timolol fixed combination (PTFC) the desired target 24-hour intraocular pressure can be reached in many glaucoma patients with the convenience of once-a-day administration and the associated high rate of adherence. Areas covered: The current role and value of FCs in the medical therapy of glaucoma is critically appraised. Special attention is paid to the PTFCs and the emerging role of preservative-free PTFCs. This review summarizes existing information on the efficacy and tolerability of the new preservative-free tafluprost/timolol FC (Taptiqom®). Expert opinion: The preservative-free tafluprost/timolol FC represents a promising stepwise treatment option for those patients whose intraocular pressure is insufficiently controlled with available monotherapy options. This novel FC has the potential to substantially improve glaucoma management and through evolution of the current glaucoma treatment paradigm, to become a core therapeutic option in the future. Nonetheless, future research is needed to better delineate the therapeutic role of current and future preservative-free FCs in glaucoma therapy.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalExpert Opinion on Pharmacotherapy
DOIs
Publication statusAccepted/In press - May 15 2016

Fingerprint

Timolol
Glaucoma
Therapeutics
Intraocular Pressure
tafluprost
Expert Testimony
Prostaglandins
Quality of Life
Pressure

Keywords

  • Glaucoma
  • preservative-free fixed combination therapy
  • tafluprost
  • tafluprost/timolol fixed combination
  • Taptiqom®
  • timolol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Preservative-free tafluprost/timolol fixed combination : a new opportunity in the treatment of glaucoma. / Konstas, Anastasios G P; Holló, G.

In: Expert Opinion on Pharmacotherapy, 15.05.2016, p. 1-13.

Research output: Contribution to journalArticle

@article{97f24e3c23424f72bdcc19a54b42678f,
title = "Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma",
abstract = "Introduction: Medical therapy of glaucoma aims to maintain the patient’s visual function and quality of life. This generally commences with monotherapy, but it is often difficult to reach the predetermined target pressure with this approach. Fixed combinations (FCs) are therefore selected as the next step of the medical therapy algorithm. By employing a prostaglandin/timolol fixed combination (PTFC) the desired target 24-hour intraocular pressure can be reached in many glaucoma patients with the convenience of once-a-day administration and the associated high rate of adherence. Areas covered: The current role and value of FCs in the medical therapy of glaucoma is critically appraised. Special attention is paid to the PTFCs and the emerging role of preservative-free PTFCs. This review summarizes existing information on the efficacy and tolerability of the new preservative-free tafluprost/timolol FC (Taptiqom{\circledR}). Expert opinion: The preservative-free tafluprost/timolol FC represents a promising stepwise treatment option for those patients whose intraocular pressure is insufficiently controlled with available monotherapy options. This novel FC has the potential to substantially improve glaucoma management and through evolution of the current glaucoma treatment paradigm, to become a core therapeutic option in the future. Nonetheless, future research is needed to better delineate the therapeutic role of current and future preservative-free FCs in glaucoma therapy.",
keywords = "Glaucoma, preservative-free fixed combination therapy, tafluprost, tafluprost/timolol fixed combination, Taptiqom{\circledR}, timolol",
author = "Konstas, {Anastasios G P} and G. Holl{\'o}",
year = "2016",
month = "5",
day = "15",
doi = "10.1080/14656566.2016.1182983",
language = "English",
pages = "1--13",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Preservative-free tafluprost/timolol fixed combination

T2 - a new opportunity in the treatment of glaucoma

AU - Konstas, Anastasios G P

AU - Holló, G.

PY - 2016/5/15

Y1 - 2016/5/15

N2 - Introduction: Medical therapy of glaucoma aims to maintain the patient’s visual function and quality of life. This generally commences with monotherapy, but it is often difficult to reach the predetermined target pressure with this approach. Fixed combinations (FCs) are therefore selected as the next step of the medical therapy algorithm. By employing a prostaglandin/timolol fixed combination (PTFC) the desired target 24-hour intraocular pressure can be reached in many glaucoma patients with the convenience of once-a-day administration and the associated high rate of adherence. Areas covered: The current role and value of FCs in the medical therapy of glaucoma is critically appraised. Special attention is paid to the PTFCs and the emerging role of preservative-free PTFCs. This review summarizes existing information on the efficacy and tolerability of the new preservative-free tafluprost/timolol FC (Taptiqom®). Expert opinion: The preservative-free tafluprost/timolol FC represents a promising stepwise treatment option for those patients whose intraocular pressure is insufficiently controlled with available monotherapy options. This novel FC has the potential to substantially improve glaucoma management and through evolution of the current glaucoma treatment paradigm, to become a core therapeutic option in the future. Nonetheless, future research is needed to better delineate the therapeutic role of current and future preservative-free FCs in glaucoma therapy.

AB - Introduction: Medical therapy of glaucoma aims to maintain the patient’s visual function and quality of life. This generally commences with monotherapy, but it is often difficult to reach the predetermined target pressure with this approach. Fixed combinations (FCs) are therefore selected as the next step of the medical therapy algorithm. By employing a prostaglandin/timolol fixed combination (PTFC) the desired target 24-hour intraocular pressure can be reached in many glaucoma patients with the convenience of once-a-day administration and the associated high rate of adherence. Areas covered: The current role and value of FCs in the medical therapy of glaucoma is critically appraised. Special attention is paid to the PTFCs and the emerging role of preservative-free PTFCs. This review summarizes existing information on the efficacy and tolerability of the new preservative-free tafluprost/timolol FC (Taptiqom®). Expert opinion: The preservative-free tafluprost/timolol FC represents a promising stepwise treatment option for those patients whose intraocular pressure is insufficiently controlled with available monotherapy options. This novel FC has the potential to substantially improve glaucoma management and through evolution of the current glaucoma treatment paradigm, to become a core therapeutic option in the future. Nonetheless, future research is needed to better delineate the therapeutic role of current and future preservative-free FCs in glaucoma therapy.

KW - Glaucoma

KW - preservative-free fixed combination therapy

KW - tafluprost

KW - tafluprost/timolol fixed combination

KW - Taptiqom®

KW - timolol

UR - http://www.scopus.com/inward/record.url?scp=84969256513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969256513&partnerID=8YFLogxK

U2 - 10.1080/14656566.2016.1182983

DO - 10.1080/14656566.2016.1182983

M3 - Article

SP - 1

EP - 13

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

ER -